Mark Balk

Statistics

Publications

Citations

H-Index

Active since

2014

Affiliations

Astellas Pharma (United States)(Current)

Mark Balk is an author at Astellas Pharma (United States) specializing in metastatic castration-resistant prostate cancer, oncology, and castration-resistant prostate cancer therapy.

Publications per year

2014–2017

Publications

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Nancy Devlin, Michael Herdman, Marco Pavesi et al. · Health and Quality of Life Outcomes · 2017 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Cat N. Bui, Ken O’Day, Scott C. Flanders et al. · Journal of Managed Care & Specialty Pharmacy · 2016 · 22 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +16

Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

Marjan Massoudi, Mark Balk, Hongbo Yang et al. · Journal of Medical Economics · 2016 · 19 citations

Medicine, Oncology, Pharmacotherapy +15

Subtype-Specific Modulation of Estrogen Receptor–Coactivator Interaction by Phosphorylation

Inga M. Tharun, Lidia Nieto, Christian Haase et al. · ACS Chemical Biology · 2014 · 16 citations

Life Sciences, Biochemistry, Molecular Biology +17

1–4 of 4